TP53 and glioblastoma: In this study, we found that there were no significant difference for OS and PFS between wild-type p53 GBM patients and mutant p53 GBM patients who received STUPP regimen, and whether GBM patients benefit from extended TMZ chemotherapy was independent of p53 mutation status, this may be related to the complicated p53 signaling pathway.